ACRS Aclaris Therapeutics, Inc.Stock Price & Overview
$1.26
Charts
Quant Ranking
ACRS Analysis
ACRS News
Latest Headlines
Ratings Summary
People Also Follow
Similar to ACRS
ETFs Holding ACRS
ACRS Company Profile
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS Revenue
ACRS Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
ACRS Ownership
ACRS Peers
Risk
Technicals
ACRS Transcripts
Investor Presentations
ACRS SEC Filings
Press Releases
ACRS Income Statement
ACRS Balance Sheet
ACRS Cash Flow Statement
ACRS Long Term Solvency
Discover More
You may be interested in: